Skip to main content
Complete Olympic Games coverage at your fingertips
Your inside track on the Olympic Games
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Complete Olympic Games coverage at your fingertips
Your inside track onthe Olympics Games
$1.99
per week
for 24 weeks
// //

Valeant chairman and CEO Michael Pearson waits for the start of their annual general meeting in Laval, Quebec May 20, 2014.

CHRISTINNE MUSCHI/Reuters

Valeant Pharmaceuticals International Inc. raised the cash component of its $49.9-billion (U.S.) hostile offer for Botox-maker Allergan Inc. and staged an elaborate defence against Allergan's attack on Valeant's business model.

But investors appeared unswayed by Laval, Que.-based Valeant's latest moves in the gloves-off, drawn-out takeover battle.

Shares of both companies dropped Wednesday, indicating that the higher bid fell short of expectations.

Story continues below advertisement

Valeant – backed by U.S. activist investor Bill Ackman – proposed to sweeten its offer with a cash increase of $10 a share to $58.30 a share, with the stock portion remaining at 0.83 of a Valeant share.

That would value the revised bid at about $49.9-billion, up from the initial offer of $47-billion. Valeant also proposed to add a contingent value right on sales of Allergan's Darpin experimental eye drug that could go to $25 per share, potentially worth an added $7.6-billion.

At about $166.16 a share, the enhanced offer falls below the $180 to $200 some investors and analysts had expected.

Valeant chairman and chief executive officer Michael Pearson said on Wednesday at a marathon New York presentation to shareholders of both companies that an analysis filed by Allergan with U.S. regulators the day before is filled with "a number of inaccuracies."

The filing, based on work by an independent forensic accounting firm and a professional services firm, said Valeant overstates its organic growth, uses overly aggressive acquisition accounting, has high senior management turnover, is overly reliant on offshore tax deferrals and has a crushing debt load.

Allergan also challenged Valeant's claims it can cut $2.7-billion in spending at Allergan without hurting R&D, sales and marketing. It claims Valeant's approach to R&D generally is to cut and slash.

Allergan CEO David Pyott has from the start insisted his company is better off as a standalone and that there is too much risk involved teaming up with an acquisition-fuelled entity such as Valeant.

Story continues below advertisement

"It's unfortunate that Allergan has not taken the time to understand our business," Mr. Pearson said at a 31/2-hour session that included lengthy individual presentations from key members of his management team.

Mr. Pearson said Valeant's organic growth has been masked by the fact that generic versions of some of its key products are coming onto market. Growth is actually in the 7- to 8-per-cent range, he said.

In a 176-page slide presentation, Valeant said it has produced double-digit organic growth so far in 2014 and has developed a leaner R&D model without sacrificing product development.

Allergan's analysis is misleading because it "cherry-picked" only some underperforming products and excluded other signifcant contributors to sales, Mr. Pearson said.

As to senior executive departures, many of them retired or left to take CEO positions elsewhere, he said.

Mr. Pearson also took aim at Allergan's own growth curve, saying its mix contains both organic and inorganic growth, with 10 acquisitions over the past 10 years.

Story continues below advertisement

Analysts were lukewarm on the revised bid.

Valeant's "new offer is better, but may not be compelling enough given [Allergan's] strong stand-alone outlook," Credit Suisse analyst Vamil Divan said in a note Wednesday.

"Given that the majority of the offer would still be in Valeant stock, how one values Valeant stock goes a long way to determining the true value of the deal."

"The offer continues to underestimate Allergan value as stand-alone entity," said Bernstein Research's Aaron Gal.

"We hoped for something more imaginative, like substantially altering the share of cash and stock Valeant will use or a more substantial increase in the value offer."

Valeant also said it has agreed to sell the rights to five anti-aging products to Nestlé SA for $1.4-billion. The deal could address antitrust concerns if its takeover of Allergan goes through.

Story continues below advertisement

Allergan said on Wednesday its board will closely review and consider Valeant's latest proposal.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies